손 습진 : 시장 인사이트, 역학 및 시장 예측(2036년)

Hand Eczema Insights and Trends

• Hand eczema is more prevalent among females, largely driven by higher exposure to "wet work" environments (e.g., healthcare, food service, domestic tasks) involving frequent handwashing and contact with irritants.
• Occupational hand eczema remains a major economic burden due to reduced productivity, absenteeism, and increased healthcare utilization.
• The average age of onset (~12 years) indicates early-life impact; patients with atopic dermatitis are at significantly higher risk due to impaired skin barrier function.
• Diagnosis is based on clinical history and physical examination, supported by tests such as patch testing, prick testing, and biopsy to determine subtype and triggers.
• Treatment is guided by severity and subtype, ranging from emollients and topical therapies (corticosteroids, calcineurin inhibitors, calcipotriol) to keratolytics for hyperkeratotic forms and systemic agents (retinoids, immunosuppressants) for severe disease.
• The regulatory progress of delgocitinib cream (ANZUPGO) in 2024, including European approval and US FDA acceptance in 2025, highlights advancement in targeted topical therapies.
• Limited systemic treatment options and regional differences in drug approvals indicate a significant unmet need in severe chronic hand eczema management.
• Increasing awareness of skin barrier dysfunction and immune-mediated pathways is driving the development of targeted therapies.
• The competitive landscape is evolving, with company such as Formation Bio/Asana BioSciences driving innovation.
• Driven by high disease burden, limited approved therapies, and growing focus on Immunomodulation, the market is poised for significant transformation.

DelveInsight's 'Hand Eczema - Market Insights, Epidemiology and Market Forecast - 2036' report delivers an in-depth understanding of the hand eczema, historical and forecasted epidemiology, as well as the Hand eczema market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.

The Hand eczema market report delivers a comprehensive analysis of the current treatment landscape, including standards of care, clinical practices, and evolving therapeutic algorithms. It evaluates, hand eczema patient burden trends, revenue & market share dynamics, peak patient share & therapy uptake analysis, and provides an in-depth market size assessment, and growth rate projections (Historical & Forecast 2022-2036) across global regions. The report highlights key unmet medical needs in hand eczema and maps the competitive and clinical landscape to uncover high-value opportunities, providing a clear outlook on future market growth potential.

Key Factors Driving the Hand Eczema Market

• High Disease Burden and Occupational Exposure

Hand eczema is one of the most common occupational skin disorders, with higher prevalence in females and individuals engaged in "wet work" occupations (e.g., healthcare, cleaning, food handling). Chronic and recurrent disease, along with its impact on quality of life and work productivity, continues to drive demand for effective therapies.

• Limited Approved Therapies and Unmet Clinical Need

Despite its prevalence, hand eczema remains an area of significant unmet need, with limited approved targeted treatments and frequent reliance on topical corticosteroids and off-label systemic agents. Suboptimal long-term control and high recurrence rates are accelerating the need for safer, more effective therapies.

• Emerging Targeted Therapies and Pipeline Innovation

The market is witnessing innovation with the development of targeted immunomodulatory treatments, including topical JAK inhibitors (e.g., delgocitinib/ANZUPGO) and other novel agents in the pipeline. Advancements led by companies such as LEO Pharma, Asana Biosciences, and Arcutis Biotherapeutics are expected to reshape the treatment landscape in the coming years.

Hand eczema Understanding and Treatment Algorithm

Hand eczema Overview and Diagnosis

Hand eczema is a chronic inflammatory skin disorder affecting the hands, characterized by erythema, scaling, vesicles, fissures, and pruritus, and often resulting from a combination of irritant and allergic exposures along with genetic predisposition. It is commonly associated with occupational risk factors, particularly "wet work" involving frequent handwashing and chemical exposure, and shows a higher prevalence among females and working-age adults. Hand eczema can occur independently or in association with atopic dermatitis, with impaired skin barrier function increasing susceptibility. The condition is broadly classified into subtypes such as irritant contact dermatitis, allergic contact dermatitis, and chronic hand eczema, each requiring tailored management. Despite its high prevalence and significant impact on quality of life and productivity, treatment options remain limited, with many patients experiencing recurrent or refractory disease, highlighting a substantial unmet clinical need.

Hand eczema Diagnosis

Diagnosis of hand eczema is based on patient history, clinical examination, and exclusion of differential diagnoses. Key history includes onset, disease course, exposures to irritants/allergens, and atopic dermatitis history. Clinical features include erythema, vesicles, scaling, hyperkeratosis, and fissures, with acute stages showing blistering and exudation and chronic stages showing infiltration and scaling. Common symptoms are pruritus and pain. Patch testing may be used to identify allergens. Early diagnosis is crucial to guide appropriate treatment and prevent chronic disease.

Hand eczema Treatment

The treatment of hand eczema begins with lifestyle modifications and avoidance of triggers, followed by medical management when needed. Core principles include patient education, identification and avoidance of irritants/allergens, and restoration of the skin barrier with emollients. First-line pharmacologic therapy involves topical anti-inflammatory agents such as corticosteroids, calcineurin inhibitors, and newer options like the pan-JAK inhibitor delgocitinib.

In severe or refractory cases, escalation to phototherapy or systemic treatments may be required. Long-term management focuses on preventing flares, maintaining skin barrier integrity, and minimizing exposure to occupational and environmental triggers to reduce recurrence and disease chronicity.

Hand Eczema Unmet Needs

The section "unmet needs of Hand eczema" outlines the critical gaps between the current state of patient care, diagnosis, and the ideal & effective management of the disease. It highlights the obstacles experienced by patients, clinicians, and researchers and identifies potential solutions for future progress.

1. Limited availability of approved targeted therapies for chronic hand eczema

2. High recurrence rates and lack of sustained disease control

3. Limited safe and effective options for severe and refractory cases

4. Challenges in accurate diagnosis and subtype differentiation

5. Lack of standardized guidelines and long-term real-world data, and others.....

Hand Eczema Epidemiology

Key Findings from Hand Eczema Epidemiological Analysis and Forecast

• Epidemiological evidence suggests that hand eczema has an annual prevalence of ~9-10% and a lifetime prevalence of up to ~15%, underscoring its high global disease burden.
• Studies indicate that chronic hand eczema (CHE) represents a smaller subset, yet it accounts for a disproportionate share of severe disease, healthcare utilization, and occupational disability.
• Secondary analysis highlights that occupational exposure particularly "wet work" is a key driver, with healthcare workers, cleaners, and food handlers showing significantly elevated risk and incidence rates.
• The occurrence of hand eczema is 1.5- to 2-fold higher in females than males. The higher prevalence in women is explained by a difference in the distribution of exposure in occupations and private life.
• More than one-third of patients experienced moderate to severe disease and around one-third had a history of atopic dermatitis.

Hand Eczema Drug Analysis & Competitive Landscape

The Hand eczema drug chapter provides a detailed, market-focused review of approved therapies and the emerging pipeline across Phase I/II-III clinical trials. It covers the mechanism of action, clinical trial data, regulatory approvals, patents, collaborations, and strategic partnerships for each therapy, along with their advantages, limitations, and recent developments. This section offers critical insights into the Hand eczema treatment landscape, supporting market assessment, competitive analysis, and growth forecasting for the Hand eczema therapeutics market.

Approved Therapies for Hand eczema

Delgocitinib (ANZUPGO): LEO Pharma

Delgocitinib cream is a topical pan-Janus kinase (JAK) inhibitor indicated for the treatment of moderate-to-severe chronic hand eczema (CHE), acting through inhibition of the JAK-STAT signaling pathway, a key driver of skin inflammation and immune dysregulation. The disease is characterized by skin barrier dysfunction, inflammatory responses, and microbiome alterations, all of which are targeted by this mechanism. In 2014, LEO Pharma A/S entered into a licensing agreement with Japan Tobacco (JT), securing exclusive global rights (excluding Japan) to develop and commercialize delgocitinib cream for dermatological use.

Alitretinoin: Stiefel Laboratories

Alitretinoin is an oral retinoid (9-cis retinoic acid) approved for the treatment of severe chronic hand eczema (CHE) unresponsive to topical corticosteroids, exerting its effect through broad anti-inflammatory and immunomodulatory activity by binding to retinoic acid receptors (RAR) and retinoid X receptors (RXR). It helps regulate keratinocyte differentiation, reduce inflammation, and restore skin barrier function, addressing key aspects of CHE pathophysiology. Alitretinoin remains one of the few approved systemic therapies for severe CHE, though its use is limited by teratogenicity and need for monitoring.

Alitretinoin Stiefel Laboratories Hand eczema Small molecule Retinoic acid receptor agonists Oral EU: 2008

Hand eczema Pipeline Analysis

Gusacitinib/ASN002 : Asana Biosciences

ASN002, an oral, potent, dual Janus Kinase (JAK) and spleen tyrosine kinase (SYK) inhibitor. Both JAK and SYK kinases are involved in both cytokine production and signaling and have been implicated in the pathogenesis of various types of lymphomas, solid tumors, myeloproliferative, and inflammation disorders.mention its current status

Hand eczema Key Players, Market Leaders and Emerging Companies

• LEO Pharma
• Stiefel Laboratories
• Formation Bio/ Asana Biosciences

Hand eczema Drug Updates

• In April 2026, LEO pharma announced that the US FDA Accepts Supplemental NDA for delgocitinib (ANZUPGO) in Adolescents of age 12-17 years with Chronic Hand Eczema.
• In March 2026, Leo Pharma announced the launch of "It's GO time", the company's new Direct-to-Consumer (DTC) multichannel campaign for ANZUPGO (delgocitinib) cream the first and only FDA-approved treatment for moderate to severe chronic hand eczema (CHE).
• In June 2025, Formation Bio Licenses Gusacitinib to Sanofi to Advance Development in New Indication.

Drug Class Insights

Hand Eczema Market Outlook

The hand eczema market is undergoing a gradual transformation, shifting from traditional symptomatic management toward targeted and mechanism-driven therapies. Current treatment approaches primarily rely on topical corticosteroids, emollients, barrier protection, and trigger avoidance; however, these strategies often provide suboptimal long-term control, particularly in moderate-to-severe cases, highlighting a significant unmet need. The chronic and relapsing nature of the disease, along with its substantial impact on quality of life and work productivity, necessitates more effective and durable therapeutic options.

With increasing focus on innovative immunomodulatory therapies, marketed key players such as LEO Pharma, Stiefel Laboratories, and emerging key player such as Formation Bio/Asana BioSciences, is actively advancing pipeline candidates across different stages of development. The emergence of targeted agents (e.g., JAK inhibitors and other novel mechanisms) is expected to reshape the treatment paradigm, similar to trends observed in other inflammatory dermatological conditions. In parallel, improved patient education, adherence strategies, and self-management approaches are gaining importance to enhance treatment outcomes in this chronic condition.

The market landscape is further supported by the presence of alitretinoin, the only widely approved systemic therapy for severe chronic hand eczema unresponsive to topical corticosteroids, particularly across European markets. However, the lack of approval in the United States and Japan underscores regional disparities and reinforces the need for globally approved and accessible therapies. The United States, driven by a large patient pool, high awareness, and advanced healthcare infrastructure, is expected to represent the largest market, with significant growth potential as novel therapies enter the market.

• The hand eczema treatment landscape is evolving from symptomatic management to targeted immunomodulatory therapies, driven by unmet need in chronic and severe cases.
• Current therapies provide limited long-term control, highlighting the need for more effective and durable treatment options.
• Alitretinoin is currently approved in Europe for severe cases.
• The United States is expected to dominate the market, supported by a large patient population and increasing adoption of novel therapies.
• The entry of pipeline agents from companies such as Asana Biosciences, Incyte/Novartis is expected to drive innovation and expand treatment options in the coming years.

Drug Class/Insights into Leading Emerging and Marketed Therapies in Hand eczema (2022-2036 Forecast)

The hand eczema treatment landscape comprises topical therapies, systemic treatments, and emerging targeted agents, each addressing different aspects of skin barrier dysfunction, inflammation, and immune dysregulation.

• Topical therapies: Include corticosteroids, calcineurin inhibitors, emollients, and barrier creams, which form the first-line treatment, helping to reduce inflammation, restore skin barrier function, and control mild-to-moderate disease.
• Systemic therapies: Include alitretinoin (approved in Europe), immunosuppressants (e.g., cyclosporine, methotrexate), which are used in moderate-to-severe or refractory cases to control chronic inflammation and disease progression.

Overall, topical and conventional systemic therapies define the current standard of care, while targeted immunomodulatory treatments are expected to drive future innovation and improve long-term outcomes in the hand eczema treatment landscape.

Hand eczema Drug Uptake

This section focuses on the uptake rate of potential drugs expected to be launched in the market during the forecast period (2026-2036). The analysis covers the Hand eczema drug's uptake, performance at peak, factors affecting performance during prime years of growth, patient uptake by therapy, and anticipated sales generated by each drug.

The uptake of therapies in hand eczema is expected to vary across topical, systemic, and emerging targeted treatments. Established therapies such as topical corticosteroids and emollients will continue to see moderate to-high uptake due to their role as first-line treatments, despite limitations in long-term control.

Systemic therapies like alitretinoin are expected to have moderate uptake, particularly in severe, refractory cases, though their use is constrained by regional approval limitations and safety considerations.

In contrast, targeted therapies, including JAK inhibitors such as delgocitinib and pipeline agents like gusacitinib, are anticipated to witness gradual uptake, driven by their mechanism-based approach and potential for improved long-term outcomes.

Detailed insights of emerging therapies' drug uptake is included in the report.

Market Access and Reimbursement of Hand eczema

Reimbursement is a crucial factor that affects the drug's access to the market. Often, the decision to reimburse comes down to the price of the drug relative to the benefit it produces in treated patients. To reduce the healthcare burden of these high-cost therapies, many payment models are being considered by payers and other industry insiders.

NOTE: Further Details are provided in the final report....

Hand eczema Therapies Price Scenario & Trends

Pricing and analogue assessment of Hand eczema therapies highlights evolving price dynamics structures. This section summarizes the cost of approved treatments, closest and most appropriate analogue selection for emerging therapies, and understanding of how pricing influences market access, adherence, and long-term uptake.

Further details are provided in the final report....

Industry Experts and Physician Views for Hand eczema

To keep up with Hand eczema market trends, we take Key Opinion Leaders (KOLs) and Subject Matter Experts (SMEs) opinions working in the domain through primary research to fill the data gaps and validate our secondary research. Industry experts were contacted for insights on the Hand eczema emerging therapies, evolving treatment landscape, patient adherence to conventional therapies, therapy switching trends, drug adoption and uptake, accessibility challenges, and epidemiology and real-world prescription patterns in hand eczema, including MD, PhD, Instructor, Postdoctoral Researcher, Professor, Researcher, and others.

DelveInsight's analysts connected with 10+ KOLs to gather insights at country level. Centers such as the University Hospital Heidelberg, St John's Institute of Dermatology, and Uppsala University, etc. were contacted.Their opinion helps understand and validate current and emerging Hand eczema therapies, highlight unmet medical needs, provide epidemiological context, and support strategic decisions for market access, therapy adoption, and pipeline prioritization in hand eczema.

Qualitative Analysis: SWOT and Conjoint Analysis

We perform qualitative and market Intelligence analysis using various approaches, such as SWOT analysis and conjoint analysis.

In the SWOT analysis of Hand eczema, strengths, weaknesses, opportunities, and threats in terms of disease diagnosis, patient awareness, patient burden, competitive landscape, cost-effectiveness, and geographical accessibility of therapies are provided.

Conjoint analysis analyzes emerging therapies based on relevant attributes such as safety, efficacy, frequency of administration, route of administration, and order of entry. Scoring is given based on these parameters to analyze the effectiveness of therapy.

The team of analysts analyzes promising emerging therapies based on relevant attributes such as safety, efficacy, frequency of administration, route of administration, and order of entry. In efficacy, the trial's primary and secondary outcome measures are evaluated, whereas the therapies' safety is evaluated, wherein the acceptability, tolerability, and adverse events are majorly observed. In addition, the scoring is also based on the route of administration, order of entry, probability of success, and the addressable patient pool for each therapy. According to these parameters, the final weightage score and the ranking of the emerging therapies are decided.

Scope of the Report:

• The report covers a segment of key events, an executive summary, a descriptive overview of hand eczema, explaining their causes, signs and symptoms, pathogenesis, and currently available treatments.
• Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of the diagnosis rate, and disease progression along treatment guidelines.
• Additionally, an all-inclusive account of both the current and emerging treatments, along with the elaborative profiles of late-stage and prominent therapies, will have an impact on the current treatment landscape.
• A detailed review of the Hand eczema market, historical and forecasted market size, market share by therapies, detailed assumptions, and rationale behind our approach is included in the report, covering the 7MM drug outreach.
• The report provides an edge while developing business strategies by understanding trends through SWOT analysis and expert insights/KOL views, patient journey, and treatment preferences that help in shaping and driving the 7MM Hand eczema market.

Report Insights

• Hand eczema Patient Population Forecast
• Hand eczema Therapeutics Market Size
• Hand eczema Pipeline Analysis
• Hand eczema Market Size and Trends
• Hand eczema Market Opportunity (Current and forecasted)

Report Key Strengths

• Epidemiology-based (Epi-based) Bottom-up Forecasting
• Artificial Intelligence (AI)-Enabled Market Research Report
• 11-Year Forecast
• Hand eczema Market Outlook (North America, Europe, Asia-Pacific)
• Patient Burden Trends (By Geography)
• Hand eczema Treatment Addressable Market (TAM)
• Hand eczema Competitive Landscape
• Hand eczema Major Companies Insights
• Hand eczema Price Trends and Analogue Assessment
• Hand eczema Therapies Drug Adoption/Uptake
• Hand eczema Therapies Peak Patient Share Analysis

Report Assessment

• Hand eczema Current Treatment Practices
• Hand eczema Unmet Needs
• Hand eczema Clinical Development Analysis
• Hand eczema Emerging Drugs Product Profiles
• Hand eczema Market attractiveness
• Hand eczema Qualitative Analysis (SWOT and conjoint analysis)

FAQs:

Market Insights

• What was the hand eczema market size, the market size by therapies, market share (%) distribution in 2025, and what would it look like by 2036? What are the contributing factors for this growth?
• What are the anticipated pricing variations among different geographies for the emerging therapies in the future?
• What can be the future treatment paradigm of hand eczema?
• What are the disease risks, burdens, and unmet needs of hand eczema? What will be the growth opportunities across the 7MM concerning the patient population with hand eczema?
• Who is the major future competitor in the market, and how will the competitors affect their market share?
• What are the current options for the treatment of hand eczema? What are the current guidelines for treating Hand eczema in the US, Europe, and Japan?

Reasons to Buy:

• The report will help in developing business strategies by understanding the latest trends and changing treatment dynamics driving the Hand eczema market.
• Bottom up forecasting builds from the affected population to product forecasts, delivering a robust, data driven approach ideal for new therapies and novel classes.
• Insights on patient burden/disease incidence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
• Understand the existing market opportunities in varying geographies and the growth potential over the coming years.
• Identifying strong upcoming players in the market will help devise strategies to help get ahead of competitors.
• Detailed analysis and ranking of class-wise potential current and emerging therapies under the conjoint analysis section to provide visibility around leading classes.
• To understand KOLs' perspectives on the accessibility, acceptability, and compliance-related challenges of existing treatment to overcome barriers in the future.
• Detailed insights on the unmet needs of the existing market so that the upcoming players can strengthen their development and launch strategy.
• This Artificial Intelligence (AI) enabled report summarize and simplify complex datasets with in the report into clear, actionable insights for stakeholders, investors, and healthcare providers, enabling faster, data driven decisions.

Table of Contents

1. Key Insights

2. Report Introduction

3. Executive Summary

4. Key Events

• 4.1. Key Conferences And Meetings
• 4.2. Key Transactions And Collaborations
• 4.3. News Flow

5. Epidemiology and Market Methodology of Hand eczema

6. Hand eczema Market Overview at a Glance

• 6.1. Clinical Landscape Analysis (By Molecule Type, Phase, and Route of Administration [ROA])
• 6.2. Market Share of Hand eczema By Therapies (%) in the 7MM in 2025
• 6.3. Market Share of Hand eczema By Therapies (%) in the 7MM in 2036

7. Disease Background And Overview of Hand eczema

• 7.1. Introduction
• 7.2. Clinical Manifestations
• 7.3. Etiology and Risk Factors
• 7.4. Pathophysiology
• 7.5. Diagnosis
• 7.6. Management
• 7.7. Clinical Guidelines
• 7.8. Treatment Algorithm

8. Epidemiology and Patient Population of Hand eczema

• 8.1. Key Findings
• 8.2. Assumption and Rationale
• 8.3. Total Prevalent Cases of Hand Eczema in the 7MM
• 8.4. The United States
  • 8.4.1. Total Prevalent Cases of Hand Eczema in the United States
  • 8.4.2. Age-specific Cases of Hand Eczema in the United States
  • 8.4.3. Gender-specific Cases of Hand Eczema in the United States
  • 8.4.5. Sub-specific Cases of Hand Eczema in the United States
  • 8.4.6. Severity-specific Cases of Hand Eczema in the United States
  • 8.4.7. Total Treated Cases of Hand Eczema in the United States
• 8.5. EU4 and the UK
  • 8.5.1. Total Prevalent Cases of Hand Eczema in EU4 and the UK
  • 8.5.2. Age-specific Cases of Hand Eczema in EU4 and the UK
  • 8.5.3. Gender-specific Cases of Hand Eczema in EU4 and the UK
  • 8.5.4. Sub-specific Cases of Hand Eczema in EU4 and the UK
  • 8.5.6. Severity-specific Cases of Hand Eczema in the EU4 and the UK
  • 8.5.7. Total Treated Cases of Hand Eczema in the EU4 and the UK
• 8.6. Japan
  • 8.6.1. Total Prevalent Cases of Hand Eczema in Japan
  • 8.6.2. Age-specific Cases of Hand Eczema in Japan
  • 8.6.3. Gender-specific Cases of Hand Eczema in Japan
  • 8.6.4. Sub-specific Cases of Hand Eczema in Japan
  • 8.6.5. Severity-specific Cases of Hand Eczema in Japan
  • 8.6.6. Total Treated Cases of Hand Eczema in Japan

9. Patient Journey of Hand Eczema

10. Marketed Therapies

• 10.1. Marketed Competitive Landscape of Hand Eczema
• 10.2. Delgocitinib (ANZUPGO): LEO Pharma
  • 10.2.1. Product Description
  • 10.2.2. Regulatory Milestones
  • 10.2.3. Other Developmental Activities
  • 10.2.4. Summary of Pivotal Trials
  • 10.2.5. Analyst's View
• 10.3. Alitretinoin: Stiefel Laboratories
  • 10.3.1. Product Description
  • 10.3.2. Regulatory Milestones
  • 10.3.3. Other Developmental Activities
  • 10.3.4. Summary of Pivotal Trials
  • 10.3.5. Analyst's View

11. Emerging Therapies

• 11.1. Emerging Competitive Landscape of Hand Eczema
• 11.2. Gusacitinib/ASN002 : Asana Biosciences
  • 11.2.1. Product Description
  • 11.2.2. Other Developmental Activities
  • 11.2.3. Clinical Development
  • 11.2.4. Safety and Efficacy
  • 11.2.5. Analyst's View

Continued emerging therapies will be provided in the final report.

12. Hand Eczema: Seven Major Market Analysis

• 12.1. Key Findings
• 12.2. Market Outlook
• 12.3. Conjoint Analysis
• 12.4. Key Market Forecast Assumptions
  • 12.4.1. Cost Assumptions and Rebate
  • 12.4.2. Pricing Trends
  • 12.4.3. Analogue Assessment
  • 12.4.4. Launch Year and Therapy Uptake
• 12.5. Total Market Size of Hand Eczema in the 7MM
• 12.6. United States Market Size
  • 12.6.1. Total Market Size of Hand Eczema in the United States
  • 12.6.2. Market Size of Hand Eczema by Therapies in United States
• 12.7. EU4 and the UK Market Size
  • 12.7.1. Total Market Size of Hand Eczema in EU4 and the UK
  • 12.7.2. Market Size of Hand Eczema by Therapies in EU4 and the UK
• 12.8. Japan Market Size
  • 12.8.1. Total Market Size of Hand Eczema in Japan
  • 12.8.2. Market Size of Hand Eczema by Therapies in Japan

13. Unmet Needs of Hand Eczema

14. SWOT Analysis of Hand Eczema

15. KOL Views of Hand Eczema

• 15.1. Expert/KOL Interview Highlights

16. Market Access and Reimbursement of Hand Eczema

• 16.1. United States
  • 16.1.1. Centre for Medicare and Medicaid Services (CMS)
• 16.2. EU4 and the UK
  • 16.2.1. Germany
  • 16.2.2. France
  • 16.2.3. Italy
  • 16.2.4. Spain
• 16.5. United Kingdom
• 16.3. Japan
  • 16.3.1. MHLW
• 16.4. Reimbursement Scenario and Key HTA Decisions in Hand Eczema

17. Appendix

• 17.1. Bibliography
• 17.2. Report Methodology

18. DelveInsight Capabilities

19. Disclaimer

20. About DelveInsight